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Abstract Anti-HLA class I monoclonal antibody 01.65 inhibits
the proliferative response of PHA-activated human T lympho-
cytes from peripheral blood mononuclear cells. The recruitment
rate in the cell cycle is slack and the G1 and S phases are
prolonged. Among the early events after PHA activation, only
the calcium-dependent PKC activity appears to be modified:
particulate PKC is completely depleted while cytosolic residual
PKC is reduced by 80% after MAb 01.65 treatment. We have
carried out in greater detail the study of c-myc gene regulation by
MAb 01.65 and the results are as follows: (i) c-myc RNA
transcription is normally initiated and finished, suggesting a
post-transcriptional regulation of c-myc gene expression; (ii) no
alteration in c-myc mRNA stability has been documented; (iii)
steady-state levels of c-myc mRNA expression by Northern blot
analysis and PCR amplification are decreased in the cytoplasmic
compartment, while in the nuclear compartment they appear to
be increased. Nuclear accumulation of mature mRNA after MAb
01.65 and PKC inhibitor (H7 and StSp) treatment appears to be
the most probable mechanism involved. The possible implications
of this are discussed.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Anti-HLA class I monoclonal antibodies (MAbs) inhibit
the proliferation of T-lymphocytes induced by Ca2-mobilis-
ing agonists, lectins or agents through either the CD3 or the
CD2 pathway [1^6].
Anti-HLA class I MAb 01.65 has been selected from a
panel of monomorphic anti-HLA class I MAbs for the strin-
gency of inhibition of the proliferative response of phytohae-
magglutinin (PHA)-activated T-lymphocytes [7]. The rise in
cytosolic free calcium concentration, the generation of inositol
phosphate and the formation of diacylglycerol (DAG) are
una¡ected by MAb 01.65 treatment. In contrast, membrane-
translocated PKC activity is inhibited and residual cytosolic
PKC is reduced [7^10]. Only the Ca2-dependent conventional
protein kinase C (cPKC) is a¡ected.
StSp and H7, two potent PKC inhibitors, are competitive
with MAb 01.65 to inhibit the proliferative response of PHA-
stimulated lymphocytes [11], thus indicating the existence of a
common inhibitory pathway.
Treatment of PHA-activated lymphocytes with MAb 01.65
induces a slowing down of the recruitment rate into the cell
cycle and a prolongation of the cell cycle time a¡ecting either
the G1 or the S phase [12,13]. A reduced mRNA steady-state
level of c-myc has been observed in MAb 01.65-treated lym-
phocytes.
The c-myc gene expression can be regulated at either the
transcriptional or the post-transcriptional level by transcrip-
tion elongation block or by mRNA degeneration. PKC is also
involved in c-myc expression. A di¡erential e¡ect of PKC
activation on c-myc expression during di¡erentiation or dur-
ing proliferation has been reported, while PKC inhibition
drastically reduces c-myc expression in HL-60 and U937 cell
lines [14].
After an earlier demonstration that c-myc mRNA reduction
was due to a post-transcriptional event we studied in greater
detail the mechanism of c-myc mRNA depletion in the cyto-
plasm. c-myc mRNA transcriptional elongation and stability
appear to be normal. Two independent sets of observations
suggest that a defective nuclear export of c-myc mRNA is the
most probable mechanism involved.
2. Materials and methods
2.1. Cell cultures
Peripheral blood mononuclear cells (PBMC) were isolated from
healthy donors by Ficoll/Hystopaque density gradient centrifugation.
PBMC were suspended at 1U106 cells/ml in Iscove Dulbecco modi¢ed
medium supplemented with 10% foetal calf serum, 100 U/ml penicillin
and 100 U/ml gentamicin and were incubated at 37‡C in a 10% CO2
humidi¢ed atmosphere. PHA (Murex Biotech Ltd.) was administered
at 0.5 Wg/ml; actinomycin D (Act-D, Sigma) at 5 Wg/ml; H7 ([1-(5-
isoquinolinylsulphonyl)-2]methylpiperazine) (Sigma) at 25 WM [14,15].
2.2. Monoclonal anti-HLA class I antibodies
We tested the dose-dependent inhibition of [3H]thymidine incorpo-
ration in PHA-activated T-lymphocytes induced by the following
MAbs: 01.65 and W6/32, which are directed to framework determi-
nants expressed on the heavy chain of HLA class I antigens [1,16];
XI-20.4, an anti-HLA-A and B [17]; R1.30, an anti-L2-microglobulin
[18] ; and as control P3, an anti-IgGlk obtained from pristane-primed
mice injected with X63.Ag8 murine parental myeloma cells. MAb
01.65 was selected because of the high inhibitory activity and admin-
istered at a dose of 12.5 Wg/ml.
2.3. Proliferation assay
Cultures were set in 96-well £at bottom plates and 6 h before
harvesting 1 WCi/ml [3H]thymidine (Amersham) was added. Each de-
termination was done in triplicate.
2.4. Nuclear run-on transcription assay
2^5U107 cells were harvested by centrifugation and washed in PBS
at 4‡C. Isolation of nuclei, isolation of mRNA transcripts and hybrid-
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isation of nascent transcripts were performed according to the meth-
ods described by O’Connor and Wade [19]. Dot blot was prepared
utilising 2 Wg linearised plasmids: pBR322, pMYC 7.4 and p44.2-
HLA. Elongation of nascent mRNA transcripts was performed by
digesting (a) c-myc cDNA from pMYC7.4 with ClaI to obtain a 5P
fragment corresponding to 800 bp spanning exon 2 and a 3P fragment
corresponding to 300 bp spanning exon 3; (b) H3 cDNA from
pF0535 with PvuII to obtain a 5P fragment corresponding to 1600
bp and a 3P fragment corresponding to 500 bp. 2 Wg of digested
cDNAs was subjected to electrophoresis on a 1% agarose gel, trans-
ferred to membrane and denatured on a pad of 3MM paper with 0.4
M NaOH for 10 min.
2.5. RNA isolation
5U107 cells were harvested to obtain nuclear and cytoplasmic
RNA. Cells were washed in ice-cold phosphate-bu¡ered saline and
lysed in ice-cold 0.5% Nonidet P-40, 10 mM Tris-HCl (pH 7.5), 10
mM NaCl, 10 mM MgCl2 for 5 min. The nuclear and cytoplasmic
RNA was extracted as described by Chomczynski and Sacchi [20].
2.6. Northern blotting analysis
RNA (30 Wg/lane) was electrophoresed in a 1.2% agarose gel con-
taining 6% formaldehyde and electroblotted to nylon membrane
(Zeta-Probe, BioRad). The blot was hybridised with 2U106 cpm of
c-myc cDNA from the pMYC7.4 clone and 28S cDNA from the
pCR6A1 clone labelled with [K-32P]dCTP (3000 Ci/mmol, Amersham)
using Amersham’s random primer labelling kit and washed according
to the manufacturer’s instructions. The c-myc mRNA expression was
normalised to the amount of 28S mRNA on the same membrane.
2.7. Reverse transcription and PCR
The reverse transcription was performed in a 20 Wl volume using the
Invitrogen cDNA cycle kit. The following primers were used for PCR
ampli¢cation: forward primer A: 5P-GAGACATGGTGAACCA-
GAGT-3P ; reverse primer B: 5P-GTCGAGGAGAGCAGAGAATC-
3P ; reverse primer E: 5P-AGTTGTGCTGATGTGTGGAG-3P.
2.8. Southern blotting
Southern blotting was done by standard procedure on 2% agarose
gel and hybridised with end-labeled probe F: 5P-CCAAGCTCGTCT-
CAGAGAAG-3P [Q-32P]ATP (Amersham) according to Maniatis [21].
The autoradiograms were scanned using a LKB laser densitometer.
3. Results
3.1. Nuclear run-on transcription assay
To investigate the e¡ect of MAb 01.65 on c-myc mRNA
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Fig. 3. a: Northern blot analysis of the total (A), cytoplasmic (B)
and nuclear RNA (C) of PBMC (1), PHA-activated PBMC (2) and
PBMC treated with MAb 01.65 (3). The blot was hybridised with
the 32P-labeled c-myc probe and with 32P-labeled 28S probe as
quantitative control. Cytoplasmic (b) and nuclear (c) c-myc RNA
levels were determined by RT-PCR in PHA-activated PBMC (PHA)
and PBMC treated with MAb 01.65 (MAb). The AB (358 bp) and
AE (603 bp) products were obtained after 30 cycles, subjected to
Southern blotting and hybridised with 32P-labeled F-probe.
Fig. 2. Nuclear run-on analysis of the MAb 01.65 e¡ect in c-myc
elongation. A: PHA-activated PBMC. B: PHA-activated PBMC
treated with MAb 01.65. Lane 1: pBR322 DNA as negative control.
Lane 2 corresponds to c-myc cDNA: 5P is the 800 bp fragment
spanning exon 2; 3P is the 300 bp fragment spanning exon 3. Lane
3 corresponds to H3 cDNA: 5P and 3P correspond to the 1600 bp
and 500 bp fragments respectively.
Fig. 1. Nuclear run-on analysis of the MAb 01.65 e¡ect in c-myc
gene transcription. a: PHA-activated PBMC. b: PHA-activated
PBMC treated with MAb 01.65. 1: pBR322 DNA as negative con-
trol; 2: pMYC7.4; 3: p44-HLA as positive control.
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transcription, run-on transcription assays were performed.
Nuclei were isolated from PBMC following activation with
PHA alone or PHA plus MAb 01.65 after 12 h incubation.
As shown in Fig. 1, the intensities of autoradiographic spots
were comparable in PHA-activated and in MAb 01.65-treated
PBMC suggesting that the transcriptional initiation was un-
modi¢ed. We also studied the transcriptional elongation of c-
myc gene. Nascent radiolabeled RNA transcripts were iso-
lated and hybridised to ¢lters containing (1) pBR322 DNA
as negative control ; (2) c-myc cDNAs corresponding to exon
2 (5P fragment) and to exon 3 (3P fragment); (3) H3 cDNA
probe as positive control. Comparison of the band intensities
(Fig. 2) between exon 2 and exon 3 of c-myc cDNA suggested
that the transcriptional elongation was carried out normally in
both PHA-activated PBMC and MAb 01.65-treated PHA-ac-
tivated PBMC.
3.2. c-myc mRNA stability is not altered in MAb 01.65-treated
PBMC
Experimental evidence con¢rms that the c-myc mRNA
from control culture cells is labile and decays with a t1=2 of
10^25 min [22]. We examined the e¡ect of MAb 01.65 treat-
ment on c-myc mRNA stability in PHA-activated PBMC.
MAb 01.65 treatment induced 67% inhibition of c-myc
mRNA steady-state level as compared to the PHA control
con¢rming previous results [23]. 5 min Act-D treatment
caused 60% reduction of the mRNA level in either MAb
01.65-treated or untreated control cultures. mRNA was
scarcely detectable after 20 min culture with Act-D. On the
basis of densitometric evaluation of speci¢c mRNA bands, we
obtained an exponential regression curve and the mRNA de-
cay slope was almost identical in both mRNAs from PHA
control and MAb-treated cultures: the estimated mRNA
t1=2s were 2.2 min and 2.4 min for control and MAb 01.65-
treated PBMC respectively.
3.3. Nuclear and cytoplasmic c-myc transcripts
Several investigations have described nuclear post-transcrip-
tional regulation involving changes in the accumulation of
primary (unspliced) transcripts. Nevertheless, a mechanism
involving inhibition of pre-RNA splicing could be excluded
since unspliced c-myc RNA in the nuclei of MAb 01.65-
treated cells was not detectable.
We examined by Northern blotting c-myc mRNA expres-
sion both in the nuclear and in the cytoplasmic compart-
ment to check whether the proved down-regulation by MAb
01.65 was due to nuclear accumulation. We con¢rmed a de-
crease in cytoplasmic c-myc mRNA accumulation and a sig-
ni¢cant increase of c-myc mRNA in the nuclear preparation
(Fig. 3a). These results, supported by densitometric scanning,
suggest an accumulation of mature c-myc mRNA in the nu-
cleus.
Reverse transcription and PCR was used to con¢rm the
above results. Fig. 4 shows the relative position of the oligo-
deoxynucleotide sequences that we used. As shown in Fig.
3b,c, after 30 ampli¢cation cycles AE product was already
detected in MAb 01.65-treated nuclear RNA preparation
while it was still undetectable in PHA control nuclear samples.
After 35 ampli¢cation cycles AE was also detected in PHA
control samples, but in a signi¢cantly reduced amount as
compared to MAb 01.65-treated RNA preparation (Fig.
5a,b). Cytoplasmic c-myc mRNA estimate indicated that the
AE product is decreased in MAb-treated preparation, con-
¢rming the previously reported decrease of cytoplasmic c-
myc mRNA by Northern blot. Arbitrary optical densitometry
units of AB were used to normalise AE values.
These data all together suggest that the observed decrease
of c-myc mRNA accumulation in the cytoplasm after MAb
01.65 treatment of PHA-activated PBMC was due to a defec-
tive c-myc late mRNA nuclear export.
3.4. H7 a¡ects the proliferative response of PHA-activated
PBMC and c-myc expression
H7 inhibited in a dose-dependent manner [3H]thymidine
incorporation of PHA-activated PBMC. The IC50 dose
(12.25 Wm) was used in cultures where cytoplasmic and nu-
clear c-myc mRNA were measured by Northern blot (Fig. 5c).
The results showed that cytoplasmic accumulation of c-myc
mRNA after 12 h treatment with H7 was reduced. In the
nuclear compartment, in contrast, an increase of mature c-
myc mRNA was detected, though of lower intensity than in
MAb 01.65-treated cells.
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Fig. 4. Genomic map of the c-myc gene depicting the positions of the three exons and the relative positions of the oligodeoxynucleotides A, B,
E used to amplify DNA by PCR. The oligodeoxynucleotide F was used to label the ampli¢cation products. By PCR we could obtain the fol-
lowing ampli¢cation products: 1, forward A plus reverse B = 358 bp; 2, forward A plus reverse E = 603 bp on mRNA post-splicing; 3, forward
A plus reverse E = 1978 bp on RNA pre-splicing.
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4. Discussion
During the study of the reduced proliferative response of
PHA-activated T-lymphocytes treated with anti-HLA class I
MAbs we became interested to the mechanisms leading to
deregulation of c-myc mRNA expression. We have demon-
strated, by Northern blot, a decrease of c-myc mRNA in
the cytoplasmic compartment of anti-HLA class I MAb-
treated PHA-activated T-lymphocytes [23]. Run-on experi-
ments show clearly that c-myc RNA transcription is initiated
and no di¡erence is observed between MAb 01.65-treated and
control samples. This ¢nding suggests that post-transcription-
al mechanisms of regulation of gene expression might be in-
volved.
c-myc mRNA levels can be controlled to transcription elon-
gation by a block during di¡erentiation. We have observed
that the c-myc exons 2 and 3 are transcribed in MAb 01.65-
treated cultures as in PHA control. It is, therefore, unlikely
that a transcription elongation block is responsible for the
MAb 01.65-induced decrease of c-myc mRNA accumulation
in the cytoplasm.
c-myc mRNA belongs to the group of messengers encoding
proteins such as cytokines and oncogenes, associated with G0/
G1 transition, that tend to be short-lived [24]. mRNA stability
is an important method to regulate gene expression. Actino-
mycin D tests have shown that c-myc mRNA was decreased in
the MAb 01.65-treated PBMC cultures, as compared to un-
treated control cultures. However, the decay appears to follow
the same velocity and the L50s 15P is approximately the same
as in control samples. No apparent increased instability of c-
myc mRNA is therefore detectable in MAb 01.65-treated cul-
tures. Both RT-PCR and Northern blot data con¢rm that the
c-myc mRNA level is decreased in the cytoplasm and con-
versely increased in the nucleus of MAb 01.65-treated
PBMCs. Identical results were obtained when PHA-activated
PBMC were treated with the PKC inhibitor H7. The accumu-
lation of mature c-myc mRNA in the nucleus possibly de-
pends on a modi¢cation of the mRNA nuclear export system,
induced by either MAb 01.65 or H7.
Three lines of evidence possibly trace a link between the
MAb 01.65 e¡ect on PHA-activated T-lymphocytes and the
deregulated c-myc mRNA expression.
(1) The inhibition of calcium-dependent PKC by anti-HLA
class I MAbs that we have described and characterised pre-
viously [9,10].
(2) A dual e¡ect of PKC on c-myc expression has been
described. PKC activation by phorbol esters induces HL-60
and U-937 cells to di¡erentiate along the monocytic lineage
[5,25] and the expression of c-myc is reduced [26,27]. In con-
trast, activation of PKC in resting cells induced expression of
c-myc. In addition to StSp, H7 reduces c-myc expression to
undetectable levels within 60 min in HL-60 and U-937 cells
[14,26,28]. Inhibitors related to cyclic nucleotide-dependent
protein kinases have no e¡ect on c-myc mRNA levels [26].
(3) Recent compelling evidence shows the involvement of
speci¢c hnRP proteins in cellular mRNA transport. These
proteins are also present outside the nucleus and may have
some cytoplasmic function and regulation [29,30]. It has been
suggested that mRNA is exported from the nucleus as a result
of its association with the ‘shuttling’ hnRP proteins. Speci¢c
factors could mediate the export of di¡erent classes of RNA
[31]. Recently Schaº¡er et al. [32] identi¢ed a 110 kDa nuclear
protein thought to be involved in mRNA translocation
through the nuclear pore and it is localised in the nuclear
envelope. P110 is phosphorylated by PKC and fragmented
before or during mRNA export.
Malviya and Block [33] underline the importance of PKC
present in the nucleus in contrast to signals transduced by
cytoplasmic PKC leading to a nuclear e¡ect. Nuclear PKC
is involved in the regulation of activity of proteins that are
PKC substrates and are involved in DNA replication or proc-
essing RNA. Substrates involved in nuclear RNA processing
and export are poly(A) polymerase [34] and a 106 kDa nu-
clear pore complex protein [35]. Phosphorylation of these pro-
teins by PKC leads to a decrease in nuclear envelope NTPase
activity required for mRNA export from the nucleus. The
study of viral RNA transport has provided insight into the
mechanisms of mRNA nuclear export [36]. Proteins that reg-
ulate the nuclear export of mRNA have been identi¢ed in at
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Fig. 5. The AB (358 bp) and AE (603 bp) products were obtained
after 35 cycles of ampli¢cation by RT-PCR in the cytoplasmic (a)
and nuclear (b) compartments of PHA-activated PBMC (PHA) and
PBMC treated with MAb 01.65 (MAb). Blots were subjected to
Southern blotting and hybridised with 32P-labeled F-probe. c:
Northern blot analysis of RNA in the cytoplasmic (A) and nuclear
(B) compartments of PBMC activated with PHA (1), PHA plus H7
(2), PHA plus MAb 01.65 (3). The blot was hybridised with the
32P-labeled c-myc probe. Normalisation was performed with 32P-la-
beled 28S probe.
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least three viral systems: REV of HIV-1; the complex of
adenovirus E1B 55Kda and E434Kda and the NS1 protein
of in£uenza virus. The latter protein inhibits the nuclear ex-
port of spliced RNA binding to poly(A) sequences in vitro
and in vivo. However, it has been shown that post-transla-
tional regulation takes place at the level of mRNA transport.
NS1 is a phosphoprotein that is loosed after phosphorylation
function and spliced mRNAs are released in the cytoplasm
[14,37]. Protein kinase inhibitors and methyltransferase inhib-
itors preventing phosphorylation determine loss of function of
NS1 protein and nuclear accumulation of late viral mRNAs.
All together these data suggest that post-transcriptional
modi¢cation of phosphorylated nuclear proteins is a funda-
mental step to a correct mRNA nuclear exportation.
Kinase inhibitors, such as H7 and MAb 01.65, might pre-
vent the phosphorylation of an hitherto unknown protein(s)
involved in c-myc mRNA export, determining the nuclear
accumulation.
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